These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 35739268)

  • 1. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
    Zhu AX; Abbas AR; de Galarreta MR; Guan Y; Lu S; Koeppen H; Zhang W; Hsu CH; He AR; Ryoo BY; Yau T; Kaseb AO; Burgoyne AM; Dayyani F; Spahn J; Verret W; Finn RS; Toh HC; Lujambio A; Wang Y
    Nat Med; 2022 Aug; 28(8):1599-1611. PubMed ID: 35739268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma.
    D'Alessio A; Cammarota A; Zanuso V; Pressiani T; Personeni N; Rimassa L
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):927-939. PubMed ID: 34167423
    [No Abstract]   [Full Text] [Related]  

  • 5. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
    Wen F; Zheng H; Zhang P; Liao W; Zhou K; Li Q
    Liver Int; 2021 May; 41(5):1097-1104. PubMed ID: 33556230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma.
    Badhrinarayanan S; Cotter C; Zhu H; Lin YC; Kudo M; Li D
    Future Oncol; 2024; 20(28):2049-2057. PubMed ID: 38861301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies.
    Liu X; Lu Y; Qin S
    Future Oncol; 2021 Jun; 17(17):2243-2256. PubMed ID: 33663220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
    Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Xu DZ; Hernandez S; Liu J; Huang C; Mulla S; Wang Y; Lim HY; Zhu AX; Cheng AL;
    N Engl J Med; 2020 May; 382(20):1894-1905. PubMed ID: 32402160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
    Vienot A; Jacquin M; Rebucci-Peixoto M; Pureur D; Ghiringhelli F; Assenat E; Hammel P; Rosmorduc O; Stouvenot M; Allaire M; Bouattour M; Regnault H; Fratte S; Raymond E; Soularue E; Husson-Wetzel S; Di Martino V; Muller A; Clairet AL; Fagnoni-Legat C; Adotevi O; Meurisse A; Vernerey D; Borg C
    BMC Cancer; 2023 Jul; 23(1):710. PubMed ID: 37516867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol.
    Ben Khaled N; Seidensticker M; Ricke J; Mayerle J; Oehrle B; Rössler D; Teupser D; Ehmer U; Bitzer M; Waldschmidt D; Fuchs M; Reuken PA; Lange CM; Wege H; Kandulski A; Dechêne A; Venerito M; Berres ML; Luedde T; Kubisch I; Reiter FP; De Toni EN
    Future Oncol; 2022 Apr; 18(12):1423-1435. PubMed ID: 35081747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.
    Hack SP; Spahn J; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Yopp A; Chow P; Qin S
    Future Oncol; 2020 May; 16(15):975-989. PubMed ID: 32352320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison.
    Casadei-Gardini A; Tada T; Shimose S; Kumada T; Niizeki T; Cascinu S; Cucchetti A
    Target Oncol; 2021 Mar; 16(2):249-254. PubMed ID: 33638735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
    Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
    JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
    Minot-This MS; Edeline J
    Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
    Casak SJ; Donoghue M; Fashoyin-Aje L; Jiang X; Rodriguez L; Shen YL; Xu Y; Jiang X; Liu J; Zhao H; Pierce WF; Mehta S; Goldberg KB; Theoret MR; Kluetz PG; Pazdur R; Lemery SJ
    Clin Cancer Res; 2021 Apr; 27(7):1836-1841. PubMed ID: 33139264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
    Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
    World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.